## 3 Results
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline  & & \multicolumn{3}{c}{**Univariate Analyses**} & \multicolumn{3}{c}{**Multivariate Analyses**} \\ \hline
**Variables** & **Cut-Off Values** & **Or (C19\%)** & **\(p\)-Value \({}^{*}\)** & **OR (C1 9\%)** & **\(p\)-Value \({}^{*}\)** \\ \hline GGT, U/L & \(\geq\)113 & 1.912 (1.534–2.861) & 0.0479 & 8.993 (2.11–38.311) & 0.003 \\ BMI, kg/m\({}^{2}\) & \(\geq\)30.1 & 1.544 (1.121–2.128) & 0.0079 & 5.996 (1.548–23.245) & 0.009 \\ Age, years & \(\geq\)55 & 1.347 (1.0376–1.589) & 0.0074 & 7.453 (1.889–29.401) & 0.004 \\ HOMA-IR & \(\geq\)3.3 & 3.342 (1.874–4.847) & 0.0271 & 5.879 (1.5413–22.431) & 0.009 \\ HbA1c, \(\%\) & \(\geq\)6.5 & 2.6616 (1.7613–3.446) & 0.0051 & 6.851 (1.954–19.547) & 0.002 \\ \hline \hline \end{tabular}  
* Values are statistically significant at \(p<0.05\); BMI—body mass index; GGT—gamma-glutamyltransferase; HbA1c—glycoslated hemoglobin; HOMA-IR—homeostatic model assessment of insulin resistance.  
\end{table} 
Table 4: Univariate and multivariate analyses for factors related to F3/F4 group. \begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline \multirow{2}{*}{**Variables**} & **Cut-Off Value** & **AUROC (95\% CI)** & **Std. Error** & **Sensitivity (95\% CI)** & **Specificity (95\% CI)** & **PPV (95\% CI)** & **NPV (95\%CI)** & **\(p\)-Value \({}^{*}\)** \\ \hline GGT, U/L & 113 & 0.76 (0.627–0.907) & 0.72 & 75.00\% & 75.00\% & 88.00\% & 72.00\% & 0.004 \\ \hline  & & & & (62.7–87.3\%) & (61.3–85.5\%) & (67.7–97.1\%) & (60.6–82.3\%) & \\ \hline Age, years & 55 & 0.74 (0.578–0.908) & 0.84 & 58.30\% & 80.80\% & 89.00\% & 61.30\% & 0.009 \\  & & & & (40.2–71.4\%) & (62.6–95.8\%) & (68.4–98.3\%) & (45.6–76.1\%) & \\ \hline BMI, kg/m\({}^{2}\) & 30.1 & 0.75 (0.617–0.897) & 0.71 & 67.60\% & 75.00\% & 93.00\% & 63.40\% & 0.006 \\  & & & & (49.2–78.8\%) & (60.9–85.6\%) & (78.4–97.9\%) & (46.2–77.7\%) & \\ \hline HOMA-IR, & 3.3 & 0.77 (0.616–0.924) & 0.78 & 66.70\% & 88.80\% & 95.00\% & 78.00\% & 0.004 \\  & & & & (48.7–79.4\%) & (66.3–97.1\%) & (81.2–99.3\%) & (65.4–90.9\%) & \\ \hline HbA1c, \% & 6.5 & 0.70 (0.548–0.852) & 0.78 & 64.30\% & 72.20\% & 90.50\% & 61.20\% & 0.032 \\  & & & & (48.3–80.5\%) & (59.8–82.6\%) & (69.7–99.3\%) & (58.9–75.4\%) & \\ \hline FIB-4 & 1.35 & 0.80 (0.689–0.915) & 0.58 & 82.3\% & 65.2\% & 74\% & 92.1\% & \textless{}0.001 \\  & & & & (62.9–96.6\%) & (48.3–78.8\%) & (60.7–82.9\%) & (78.5–99.9\%) & \\ \hline APRI & 1 & 0.79 (0.663–0.918) & 0.65 & 72.4\% & 87\% & 72.3\% & 89.6\% & 0.002 \\  & & & & (58.4–81.9\%) & (66.1–97.3\%) & (57.9–80.1\%) & (67.8–98.1\%) & \\ \hline NFS & \textgreater{}0.65 & 0.82 (0.67–0.93) & 0.63 & 78.4\% & 63.2\% & 67.4\% & 94.3\% & \\ \hline  & & & (61.2–89.2\%) & (50.1–79.5\%) & (52.8–81.3\%) & (79.4–99.3\%) & \textless{}0.001 \\ \hline \hline \end{tabular}  
* Values are statistically significant at \(p<0.05\); BMI—body mass index; GGT—gamma-glutamyltransferase; HbA1c—glycoslated hemoglobin; HOMA-IR—homeostatic model assessment of insulin resistance; FIB-4–Fibrosis 4; APRI—AST-to-platelet ratio index.  
\end{table} 
Table 3: Diagnostic performances of different parameters in predicting severe liver fibrosis.